BioCentury | Feb 23, 2015
Emerging Company Profile

Eyeing new antibiotics

Traditional antibiotics kill bacteria by inhibiting protein, DNA, or cell wall synthesis but require multiplying cells to be effective. SinSa Laboratories Inc .'s peptide antibiotics kill slow- and fast-growing bacteria by direct disruption of the...
BioCentury | Sep 26, 2013
Distillery Techniques

Technology: Chemistry

This week in techniques Approach Summary Licensing status Publication and contact information Chemistry Synthesis of simaomicin-a to enable derivatization A method to synthesize the natural compound simaomicin-a could help the development of analogs for use...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoid X receptor-a (RXRA; RXRa); tumor necrosis factor-a (TNF-a) Cell culture studies suggest a xanthone called CF31, isolated from the Cratoxylum formosum plant, could...
BioCentury | Jul 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Aromatase In vitro studies identified xanthone-based aromatase inhibitors that could help treat hormone-dependent breast cancer. Derivatives of the generic aromatase inhibitor xanthone showed...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...8/01 Cogent $15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon...
BioCentury | Dec 10, 2001
Company News

Xanthon management update

Xanthon Inc., Research Triangle Park, N.C. Business: Bioinformatics Promoted: Neil Moore to VP from director of business development WIR Staff...
BioCentury | Aug 27, 2001
Company News

Chiron, Xanthon deal

...The companies will use an electrochemical DNA detection system from Xanthon with CHIR's HCV nucleic acid...
...develop a system to detect infectious agents in clinical samples. Chiron Corp. (CHIR), Emeryville, Calif. Xanthon Inc....
BioCentury | Aug 27, 2001
Finance

Money Hunters

...Northwest Bio $13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...Northwest Bio $13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon...
BioCentury | Aug 20, 2001
Company News

Xanthon, Chiron diagnostic deal

...The companies will use an electrochemical DNA detection system from Xanthon ( Research Triangle Park, N.C...
Items per page:
1 - 10 of 37
BioCentury | Feb 23, 2015
Emerging Company Profile

Eyeing new antibiotics

Traditional antibiotics kill bacteria by inhibiting protein, DNA, or cell wall synthesis but require multiplying cells to be effective. SinSa Laboratories Inc .'s peptide antibiotics kill slow- and fast-growing bacteria by direct disruption of the...
BioCentury | Sep 26, 2013
Distillery Techniques

Technology: Chemistry

This week in techniques Approach Summary Licensing status Publication and contact information Chemistry Synthesis of simaomicin-a to enable derivatization A method to synthesize the natural compound simaomicin-a could help the development of analogs for use...
BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Retinoid X receptor-a (RXRA; RXRa); tumor necrosis factor-a (TNF-a) Cell culture studies suggest a xanthone called CF31, isolated from the Cratoxylum formosum plant, could...
BioCentury | Jul 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Aromatase In vitro studies identified xanthone-based aromatase inhibitors that could help treat hormone-dependent breast cancer. Derivatives of the generic aromatase inhibitor xanthone showed...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...8/01 Cogent $15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon...
BioCentury | Dec 10, 2001
Company News

Xanthon management update

Xanthon Inc., Research Triangle Park, N.C. Business: Bioinformatics Promoted: Neil Moore to VP from director of business development WIR Staff...
BioCentury | Aug 27, 2001
Company News

Chiron, Xanthon deal

...The companies will use an electrochemical DNA detection system from Xanthon with CHIR's HCV nucleic acid...
...develop a system to detect infectious agents in clinical samples. Chiron Corp. (CHIR), Emeryville, Calif. Xanthon Inc....
BioCentury | Aug 27, 2001
Finance

Money Hunters

...Northwest Bio $13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...Northwest Bio $13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon...
BioCentury | Aug 20, 2001
Company News

Xanthon, Chiron diagnostic deal

...The companies will use an electrochemical DNA detection system from Xanthon ( Research Triangle Park, N.C...
Items per page:
1 - 10 of 37